Joseph Mikhael, MD

Articles

Barriers in the Diagnosis of Multiple Myeloma for Patients

October 13th 2022

Craig Cole, MD, describes the barriers that can affect the diagnosis of multiple myeloma.

Examining the Roots of Health Disparities in Multiple Myeloma

October 13th 2022

Joseph Mikhael, MD, introduces the topic of disparities in multiple myeloma and the concept of multicultural health care.

Multiple Myeloma: Disparities in Access to Transplantation and Novel Therapy

October 7th 2022

Closing out their review of the barriers racial and ethnic minority groups encounter in receiving care, expert panelists address access to transplantation or novel therapy.

Multiple Myeloma: Disparities in Access to Specialized Care

October 7th 2022

Comprehensive discussion on access to specialized care and how racial and ethnic minority groups encounter barriers in this setting.

Multiple Myeloma: Disparities in Time to Diagnosis

September 30th 2022

Panelists address how racial and ethnic minority groups experience disparity in time to diagnosis within the multiple myeloma treatment pathway.

Societal Determinants of Health in Multiple Myeloma

September 30th 2022

Expert panelists shift their attention to how social determinants of multiple myeloma impact the treatment received by racial and ethnic minority groups.

Biological Determinants of Health in Multiple Myeloma

September 23rd 2022

Focused discussion on the biological determinants of multiple myeloma and how its prevalence is reflected in racial and ethnic minority groups.

Overview of Multiple Myeloma and Health Equity

September 23rd 2022

Joseph Mikhael, MD, spearheads an overview on the prevalence of multiple myeloma in racial and ethnic minority groups in the context of health equity.

Addition of Isatuximab to RVd as Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma (GMMG-HD7)

January 27th 2022

Expert hematologist/oncologist Joseph Mikhael, MD, shares insight on the phase III GMMG-HD7 trial, which added isatuximab to RVd in the setting of newly diagnosed, transplant-eligible multiple myeloma.

Dr. Mikhael on the Promise of Bispecific Antibodies in Multiple Myeloma

November 12th 2021

Joseph Mikhael, MD, discusses the promise of bispecific antibodies in multiple myeloma.

Dr. Mikhael on Treatment Selection for Early Relapse in Multiple Myeloma

August 9th 2021

Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.

Dr. Mikhael on the Advances Made in Multiple Myeloma Treatment

December 2nd 2020

Joseph Mikhael, MD, discusses novel agents used to treat patients with multiple myeloma.

Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma

November 24th 2020

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Dr. Mikhael on Unmet Needs in Triple-Class Refractory Multiple Myeloma

November 19th 2020

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.